Use of adenine-derived compounds for the treatment of lupus
US8058281B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 6, 2007 |
| Grant date | Nov 15, 2011 |
| Priority date | — |
| Expiry date | Mar 6, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a method of treating systemic lupus erythematosus comprising administering a compound of formula (I)
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.